Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis

Steven A. Mazzuca, K. D. Brandt, D. R. Eyre, Barry Katz, J. Askew, K. A. Lane

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To determine whether urinary concentrations of the cross linked C-telopeptide of type II collagen (CTx-II) distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Methods: Subjects were 120 obese women with unilateral knee osteoarthritis who participated in a 30 month, randomised, placebo controlled trial of structure modification by doxycycline, in which a standardised semiflexed anteroposterior view of the knee was obtained at baseline and 30 months. Subjects were selected from a larger sample to permit comparisons of urinary CTx-II levels between 60 progressors and 60 non-progressors with respect to medial joint space narrowing. Each group contained 30 subjects who, across five semi-annual assessments, reported on at least two occasions an increase of ≥20% in 50 ft walk pain (minimum = 1 cm on a 10 cm visual analogue scale), relative to the previous visit, he remainder reported no increases in knee pain. Urine samples were obtained semi-annually for determination of the CTx-II and creatinine concentrations. Results: In an analysis of the placebo group only, the frequency of radiographic progressors in the upper and middle fertiles (48% and 60%, respectively) of the baseline CTx-II distribution was not significantly different than that in the lower fertile (64%). These results were unchanged after inclusion of data from subjects in the doxycycline group. Furthermore, serial CTx-II levels did not distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Conclusions: In this pilot study, urinary CTx-II concentration was not a useful biomarker of osteoarthritis progression.

Original languageEnglish
Pages (from-to)1055-1059
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume65
Issue number8
DOIs
StatePublished - Aug 2006

Fingerprint

Knee Osteoarthritis
Doxycycline
Joints
Collagen Type II
Knee
Biomarkers
Placebos
Pain
Creatinine
Visual Analog Scale
Osteoarthritis
Randomized Controlled Trials
Urine
collagen II C-telopeptide
collagen type I trimeric cross-linked peptide

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. / Mazzuca, Steven A.; Brandt, K. D.; Eyre, D. R.; Katz, Barry; Askew, J.; Lane, K. A.

In: Annals of the Rheumatic Diseases, Vol. 65, No. 8, 08.2006, p. 1055-1059.

Research output: Contribution to journalArticle

Mazzuca, Steven A. ; Brandt, K. D. ; Eyre, D. R. ; Katz, Barry ; Askew, J. ; Lane, K. A. / Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. In: Annals of the Rheumatic Diseases. 2006 ; Vol. 65, No. 8. pp. 1055-1059.
@article{d12852cb1f2b45ae9f09a79e57bcb89f,
title = "Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis",
abstract = "Objective: To determine whether urinary concentrations of the cross linked C-telopeptide of type II collagen (CTx-II) distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Methods: Subjects were 120 obese women with unilateral knee osteoarthritis who participated in a 30 month, randomised, placebo controlled trial of structure modification by doxycycline, in which a standardised semiflexed anteroposterior view of the knee was obtained at baseline and 30 months. Subjects were selected from a larger sample to permit comparisons of urinary CTx-II levels between 60 progressors and 60 non-progressors with respect to medial joint space narrowing. Each group contained 30 subjects who, across five semi-annual assessments, reported on at least two occasions an increase of ≥20{\%} in 50 ft walk pain (minimum = 1 cm on a 10 cm visual analogue scale), relative to the previous visit, he remainder reported no increases in knee pain. Urine samples were obtained semi-annually for determination of the CTx-II and creatinine concentrations. Results: In an analysis of the placebo group only, the frequency of radiographic progressors in the upper and middle fertiles (48{\%} and 60{\%}, respectively) of the baseline CTx-II distribution was not significantly different than that in the lower fertile (64{\%}). These results were unchanged after inclusion of data from subjects in the doxycycline group. Furthermore, serial CTx-II levels did not distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Conclusions: In this pilot study, urinary CTx-II concentration was not a useful biomarker of osteoarthritis progression.",
author = "Mazzuca, {Steven A.} and Brandt, {K. D.} and Eyre, {D. R.} and Barry Katz and J. Askew and Lane, {K. A.}",
year = "2006",
month = "8",
doi = "10.1136/ard.2005.041582",
language = "English",
volume = "65",
pages = "1055--1059",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis

AU - Mazzuca, Steven A.

AU - Brandt, K. D.

AU - Eyre, D. R.

AU - Katz, Barry

AU - Askew, J.

AU - Lane, K. A.

PY - 2006/8

Y1 - 2006/8

N2 - Objective: To determine whether urinary concentrations of the cross linked C-telopeptide of type II collagen (CTx-II) distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Methods: Subjects were 120 obese women with unilateral knee osteoarthritis who participated in a 30 month, randomised, placebo controlled trial of structure modification by doxycycline, in which a standardised semiflexed anteroposterior view of the knee was obtained at baseline and 30 months. Subjects were selected from a larger sample to permit comparisons of urinary CTx-II levels between 60 progressors and 60 non-progressors with respect to medial joint space narrowing. Each group contained 30 subjects who, across five semi-annual assessments, reported on at least two occasions an increase of ≥20% in 50 ft walk pain (minimum = 1 cm on a 10 cm visual analogue scale), relative to the previous visit, he remainder reported no increases in knee pain. Urine samples were obtained semi-annually for determination of the CTx-II and creatinine concentrations. Results: In an analysis of the placebo group only, the frequency of radiographic progressors in the upper and middle fertiles (48% and 60%, respectively) of the baseline CTx-II distribution was not significantly different than that in the lower fertile (64%). These results were unchanged after inclusion of data from subjects in the doxycycline group. Furthermore, serial CTx-II levels did not distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Conclusions: In this pilot study, urinary CTx-II concentration was not a useful biomarker of osteoarthritis progression.

AB - Objective: To determine whether urinary concentrations of the cross linked C-telopeptide of type II collagen (CTx-II) distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Methods: Subjects were 120 obese women with unilateral knee osteoarthritis who participated in a 30 month, randomised, placebo controlled trial of structure modification by doxycycline, in which a standardised semiflexed anteroposterior view of the knee was obtained at baseline and 30 months. Subjects were selected from a larger sample to permit comparisons of urinary CTx-II levels between 60 progressors and 60 non-progressors with respect to medial joint space narrowing. Each group contained 30 subjects who, across five semi-annual assessments, reported on at least two occasions an increase of ≥20% in 50 ft walk pain (minimum = 1 cm on a 10 cm visual analogue scale), relative to the previous visit, he remainder reported no increases in knee pain. Urine samples were obtained semi-annually for determination of the CTx-II and creatinine concentrations. Results: In an analysis of the placebo group only, the frequency of radiographic progressors in the upper and middle fertiles (48% and 60%, respectively) of the baseline CTx-II distribution was not significantly different than that in the lower fertile (64%). These results were unchanged after inclusion of data from subjects in the doxycycline group. Furthermore, serial CTx-II levels did not distinguish subjects with progressive radiographic or symptomatic knee osteoarthritis from those with stable disease. Conclusions: In this pilot study, urinary CTx-II concentration was not a useful biomarker of osteoarthritis progression.

UR - http://www.scopus.com/inward/record.url?scp=33746483913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746483913&partnerID=8YFLogxK

U2 - 10.1136/ard.2005.041582

DO - 10.1136/ard.2005.041582

M3 - Article

C2 - 16339292

AN - SCOPUS:33746483913

VL - 65

SP - 1055

EP - 1059

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 8

ER -